Blog
Norwich Clinical Services (NCS) receives facility approval from ANVISA again
Norwich Clinical is pleased to announce that it has successfully been inspected by ANVISA again in late 2015.
We are now qualified through 2017 to perform studies for Brazilian submission. NCS had been previously inspected by ANVISA along with MOH Turkey, FDA, EMA, WHO and DCGI. ANVISA like MOH Turkey require facility approvals in order for pharmaceutical companies to submit studies to Brazil and Turkey respectively.
Our team has been busy through 2015 with FDA, EMA and ANVISA visiting our facilities and inspecting our Clinical and Bioanalytical operations. We are proud to have completed these successful audits.
Finally, we got word from a sponsor that they have started to receive FDA approval from work completed at NCS. Norwich Clinical is very proud of this fact and thanked the company for the positive information. Our company goal is to provide Comprehensive, Internationally Compliant, and Timely Clinical, Bioanalytical and Pharmacovigilance Services to our sponsors.